[
  {
    "ts": null,
    "headline": "Goldman Sachs 4 New Conviction List Stocks Offer Dividends and Growth",
    "summary": "Here are the four new stock additions to the Goldman Sachs Conviction List for October—all outstanding total return ideas for growth and income investors.",
    "url": "https://finnhub.io/api/news?id=8ebad2de55087d508df93e9eaea56e3c9ed886f5c1dc5f13f84bbd729b5bb96e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760710394,
      "headline": "Goldman Sachs 4 New Conviction List Stocks Offer Dividends and Growth",
      "id": 137164335,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Here are the four new stock additions to the Goldman Sachs Conviction List for October—all outstanding total return ideas for growth and income investors.",
      "url": "https://finnhub.io/api/news?id=8ebad2de55087d508df93e9eaea56e3c9ed886f5c1dc5f13f84bbd729b5bb96e"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: American Express beats estimates, EssilorLuxottica stock surges as focus turns to regional bank earnings",
    "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=a0f0e795f70e788148a98c919047799b817afe11a7d13c90b0264c2a164589f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760703163,
      "headline": "Earnings live: American Express beats estimates, EssilorLuxottica stock surges as focus turns to regional bank earnings",
      "id": 137125633,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=a0f0e795f70e788148a98c919047799b817afe11a7d13c90b0264c2a164589f4"
    }
  },
  {
    "ts": null,
    "headline": "What Catalysts Could Shift the Narrative for Abbott as Analysts Weigh New Developments",
    "summary": "Abbott Laboratories' consensus analyst price target has seen a modest uptick, increasing from $142.48 to $144.40 following the company’s latest earnings update. This change reflects a blend of ongoing optimism about Abbott’s medical device growth and robust international presence, as well as some lingering concerns over near-term challenges. Stay tuned to discover how you can track these evolving perspectives and remain informed about Abbott’s shifting investment outlook. What Wall Street Has...",
    "url": "https://finnhub.io/api/news?id=ea41534bbf16674214142a00b03a04d50c44784eb924a731b329cffb2dd5e63d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760685590,
      "headline": "What Catalysts Could Shift the Narrative for Abbott as Analysts Weigh New Developments",
      "id": 137121847,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott Laboratories' consensus analyst price target has seen a modest uptick, increasing from $142.48 to $144.40 following the company’s latest earnings update. This change reflects a blend of ongoing optimism about Abbott’s medical device growth and robust international presence, as well as some lingering concerns over near-term challenges. Stay tuned to discover how you can track these evolving perspectives and remain informed about Abbott’s shifting investment outlook. What Wall Street Has...",
      "url": "https://finnhub.io/api/news?id=ea41534bbf16674214142a00b03a04d50c44784eb924a731b329cffb2dd5e63d"
    }
  },
  {
    "ts": null,
    "headline": "RBC Capital Reiterates Abbott Laboratories (ABT) Outperform Recommendation",
    "summary": "RBC Capital Reiterates Abbott Laboratories (ABT) Outperform Recommendation",
    "url": "https://finnhub.io/api/news?id=542cf5b262afd1c69bb5bcb1a5877a4638be52d485d66cddd30a72b474036bb3",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760659651,
      "headline": "RBC Capital Reiterates Abbott Laboratories (ABT) Outperform Recommendation",
      "id": 137119126,
      "image": "",
      "related": "ABT",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=542cf5b262afd1c69bb5bcb1a5877a4638be52d485d66cddd30a72b474036bb3"
    }
  },
  {
    "ts": null,
    "headline": "Wells Fargo Maintains Abbott Laboratories (ABT) Overweight Recommendation",
    "summary": "Wells Fargo Maintains Abbott Laboratories (ABT) Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=27ccd506109600080987e824169378229176e016c48bcb565442a72784485c6e",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760659642,
      "headline": "Wells Fargo Maintains Abbott Laboratories (ABT) Overweight Recommendation",
      "id": 137119128,
      "image": "",
      "related": "ABT",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=27ccd506109600080987e824169378229176e016c48bcb565442a72784485c6e"
    }
  },
  {
    "ts": null,
    "headline": "Raymond James Maintains Abbott Laboratories (ABT) Outperform Recommendation",
    "summary": "Raymond James Maintains Abbott Laboratories (ABT) Outperform Recommendation",
    "url": "https://finnhub.io/api/news?id=eb8380a563f26f51f28355705cbd1f50cef6671bb733110c09288bd5cfebf3dc",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760659456,
      "headline": "Raymond James Maintains Abbott Laboratories (ABT) Outperform Recommendation",
      "id": 137119190,
      "image": "",
      "related": "ABT",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=eb8380a563f26f51f28355705cbd1f50cef6671bb733110c09288bd5cfebf3dc"
    }
  },
  {
    "ts": null,
    "headline": "Evercore ISI Group Maintains Abbott Laboratories (ABT) Outperform Recommendation",
    "summary": "Evercore ISI Group Maintains Abbott Laboratories (ABT) Outperform Recommendation",
    "url": "https://finnhub.io/api/news?id=c0dd6dd53316280c1e181a7e06536409d4ebb9f9881b78005d51a31b7ab02e31",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760659381,
      "headline": "Evercore ISI Group Maintains Abbott Laboratories (ABT) Outperform Recommendation",
      "id": 137119207,
      "image": "",
      "related": "ABT",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=c0dd6dd53316280c1e181a7e06536409d4ebb9f9881b78005d51a31b7ab02e31"
    }
  }
]